An Observational Study of Avastin (Bevacizumab) in Combination With Paclitaxel in First-Line Treatment in Patients With HER2-Negative Metastatic Breast Cancer

Hoffmann-La Roche16 enrolled

Overview

This prospective observational study will evaluate the use in clinical practice, efficacy and safety of Avastin (bevacizumab) in combination with paclitaxel in first line in patients with HER2-negative metastatic breast cancer. Data will be collected from eligible patients for up to 2.5 years.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Breast Cancer

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult patients, \>/= 18 years of age * Locally recurrent or metastatic breast cancer * No prior treatment for metastatic or locally recurrent disease * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 Exclusion Criteria: * History or clinical evidence of brain metastases * Pregnancy * Uncontrolled hypertension ( systolic \> 150 mmHg and/or diastolic \> 100 mmHg) or clinically significant (i.e. active) cardiovascular disease * Major surgical procedure or significant traumatic injury within 28 days prior to enrolment

Locations (2)

Uni Hospital Split; Oncology & Radiotherapy

Split, Croatia

General Hospital Varazdin

Varaždin, Croatia

Outcomes

Primary Outcomes

Progression-free survival

Time frame: approximately 2.5 years

Secondary Outcomes

Dosage/schedule/number of cycles of Avastin treatment in clinical practice

Time frame: approximately 2.5 years

Safety: Incidence of adverse events

Time frame: approximately 2.5 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.